The effect of propolis supplementation in improving antioxidant status: A systematic review and meta‐analysis of controlled clinical trials

Abstract The present study aimed to assess the effect of propolis supplementation on oxidative status, a key contributor to the etiology of many chronic diseases. A systematic search of multiple databases, including Web of Science, SCOPUS, Embase, PubMed, and Google Scholar, was conducted from inception to October 2022 to identify articles examining the effect of propolis on glutathione (GSH), glutathione peroxidase (GPX), total antioxidant capacity (TAC), superoxide dismutase (SOD), and malondialdehyde (MDA) levels. The quality of the included studies was evaluated using the Cochrane Collaboration tool. A total of nine studies were included in the final analysis, and a random‐effects model was used to pool the estimated effects. Results showed that propolis supplementation significantly increased the levels of GSH (SMD = 3.16; 95% CI: 1.15, 5.18; I 2 = 97.2%), GPX (SMD = 0.56; 95% CI: 0.07, 1.05; p = 0.025; I 2 = 62.3%), and TAC (SMD = 3.26; 95% CI: 0.89, 5.62; I 2 = 97.8%, p < 0.001). However, the effect of propolis on SOD was not significant (SMD = 0.05; 95% CI: −0.25, 0.34; I 2 = 0.0%). Although the MDA concentration was not significantly decreased overall (SMD = −0.85, 95% CI: −1.70, 0.09; I 2 = 93.3%), a significant decrease in MDA levels was observed at doses ≥1000 mg/day (SMD = −1.90; 95% CI: −2.97, −0.82; I 2 = 86.4) and supplementation durations of less than 11 weeks (SMD = −1.56; 95% CI: −2.60, −0.51; I 2 = 90.4). These results suggest that propolis is a safe supplement with a beneficial effect on GSH, GPX, and TAC levels and may be an effective adjunctive therapy for diseases where oxidative stress is a key factor in the etiology. However, further high‐quality studies are necessary to make more precise and comprehensive recommendations given the limited number of studies, clinical diversity, and other limitations.